FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

106 letters match. Newest first.

  1. Synthetix Inc. DBA Helix Chemical Supply

    FDA says Synthetix Inc., doing business as Helix Chemical Supply, sold unapproved and misbranded Semaglutide and Tirzepatide drugs online.

    High risk
  2. Samm Solutions, Inc., d.b.a. BTS Research

    Samm Solutions/BTS Research failed good laboratory practice (GLP) rules for nonclinical drug studies, FDA says.

    Medium
  3. www.semaspace.com

    FDA warned semaspace.com for selling unapproved, misbranded injectable semaglutide drugs online without prescriptions.

    High risk
  4. www.gorillahealing.com

    FDA warned gorillahealing.com for selling unapproved, misbranded semaglutide and tirzepatide drugs to U.S. consumers online.

    High risk
  5. Valley Biosystems

    FDA cited Valley Biosystems, a California biologics testing lab, for Good Laboratory Practice violations that call its nonclinical study data into question.

    High risk
  6. Toxikon Corporation/Labcorp Bedford LLC

    FDA warned Toxikon/Labcorp Bedford over GLP violations in a biologics nonclinical study, including incorrect kidney-function calculations and failed QA review.

    Medium